Galderma Group AG/ADR
GDERFDrugs in Pipeline
9
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
botulinum toxin
Lateral Canthal Lines
Nemolizumab
Moderate-to-Severe Atopic Dermatitis
botulinum toxin neuromodulator
Glabellar Frown Lines (GL)
CD07805/47 gel
Rosacea
QM1114-DP
Glabellar Frown Lines
Metvix® cream
Basal Cell Carcinoma
Botulinum Toxin Type A
Glabellar Frown Lines
CD 2027
Plaque-type Psoriasis
Adapalene
Acne Scars
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
botulinum toxin | Phase 3 | Lateral Canthal Lines | - | - |
Nemolizumab | Phase 3 | Moderate-to-Severe Atopic Dermatitis | - | - |
botulinum toxin neuromodulator | Phase 3 | Glabellar Frown Lines (GL) | - | - |
CD07805/47 gel | Phase 3 | Rosacea | - | - |
QM1114-DP | Phase 3 | Glabellar Frown Lines | - | - |
Metvix® cream | Phase 3 | Basal Cell Carcinoma | - | - |
Botulinum Toxin Type A | Phase 2 | Glabellar Frown Lines | - | - |
CD 2027 | Phase 2 | Plaque-type Psoriasis | - | - |
Adapalene | Phase 2 | Acne Scars | - | - |